Angioplasty to common femoral artery begins to emerge as an alternative to surgery

Original title: Acute and Medium-Term Outcomes of Endovascular Therapy of Obstructive Disease of Diverse Etiology of the Common Femoral Artery. Reference: Philip B. Dattilo et al. Catheterization and Cardiovascular Interventions 81:1013–1022 (2013).

Surgical endarterectomy is established as the gold standard for treating injuries to common femoral artery since angioplasty presents some difficulties due to the risk of compromising the deep femoral artery or the physical forces to which it is subjected when segmenting a stent. Despite the above, there are emerging studies supporting angioplasty as an alternative to surgery.

 This study included 30 patients of whom 22 had chronic atherosclerotic lesions and 8 acute ischemia due to complications from access by percutaneous closure devices. The overall technical success in this cohort was 90% (given the inability to cross the lesion in 3 patients who were eventually referred for surgery). A stent was used in only one patient, with the initial intention to only perform balloon angioplasty combined with different atherectomy devices. The primary and secondary patency at two years follow-up was 83% ± 8% and 86% ± 7%, respectively. All those who showed restenosis had originally developed atherosclerotic lesions.

Conclusion:

In this series of consecutive patients with injury to the common femoral artery of various etiologies, balloon angioplasty combined with atherectomy devices had acceptable results without stent implants or deep femoral compromise. The excellent primary patency observed in patients with injuries due to the use of percutaneous closure devices suggests endovascular treatment as the first option for this group of patients.

Commentary:

The ability to successfully resolve our own complications, such as those associated with percutaneous closure device, is good news. However, angioplasty for atherosclerotic lesions in the common femoral artery should still be reserved for patients with contraindications to surgery.

SOLACI.ORG

More articles by this author

A New Asymptomatic Carotid Stenosis Paradigm? CREST-2 Trial Unified Results

Severe asymptomatic carotid stenosis continues to be controversial seeing the optimization of intensive medical therapy (IMT) and the availability lower periprocedural risk revascularization techniques....

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...